


# Supplemental Figure 1



Supplementary Figure 1. (A) T cells obtained from peripheral blood samples from consenting healthy adult donors and a patient with myeloma were transduced to express a construct containing an extracellular BCMA binding scFv and intracellular 41BBz endodomain. (B) Binder #1 was selected over other binders, including binder #2, for its ability to robustly produce cytokines in the presence of RPMI-8226 cells. The addition of lenalidomide increased cytokine levels in both binder #1 and binder #2. (C) Anti-BCMA CAR T materials from 3 healthy donors and 1 patient donor were assessed for cytolytic activity at 1:1 E:T ratio against OPM-2 and RPMI-8226 cell lines. (D) Baseline cytolytic activity across donors is represented by calculating the area under the curve (AUC) for both 0.3:1 and 1:1 E:T ratios for both OPM-2 and RPMI-8226 cell lines. Baseline cytokine production for IFN- $\gamma$ , IL-2, and TNF for OPM-2 (E) and RPMI-8226 (F) cell lines.